SEQUENCE LISTING

<110> DiMarchi, Richard

<120> Glucagon/GLP-1 Receptor Co-Agonists

<130> 31135/46342 PCT

<150> US-61/500,027
<151> 2011-06-22

<150> US-61/547,360
<151> 2011-10-14

<160> 22

<170> PatentIn version 3.5

<210> 1
<211> 29
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Native human glucagon

<400> 1

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15

Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr
20 25

<210> 2
<211> 37
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> GLP-1

<400> 2

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu
20 25 30

Val Lys Gly Arg Gly
35

<210> 3
<211> 33
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> GLP-2

<400> 3

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
20 25 30

Asp

<210> 4
<211> 37
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Oxyntomodulin

<400> 4

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15

Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr Lys Arg Asn
20 25 30

Arg Asn Asn Ile Ala
35

<210> 5
<211> 30
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> GLP1 (7-36 amide)

<220>
<221> MOD_RES
<222> (30)..(30)
<223> C-terminal amidation

<400> 5

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
20 25 30

<210> 6

<211> 31
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> GLP-1 (7-37 acid)

<400> 6

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
20 25 30

<210> 7
<211> 39
<212> PRT
<213> Heloderma suspectum

<220>
<221> MISC_FEATURE
<223> Exendin-4

<400> 7

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 8

Lys Arg Asn Arg Asn Asn Ile Ala
1 5

<210> 9
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 9

Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser

1 5 10

<210> 10
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 10

Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser
1 5 10

<210> 11
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 11

Lys Arg Asn Arg
1

<210> 12
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu spacer

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is AIB

<220>
<221> MOD_RES
<222> (31)..(31)
<223> Xaa is gamma-Glu

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> C-terminal amidation

<400> 12

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr Lys Xaa
20 25 30

<210> 13
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MOD_RES
<222> (20)..(20)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (24)..(24)
<223> Covalently bound to PEG

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Xaa is gamma-Glu

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> C-terminal amidation

<400> 13

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15

Arg Arg Ala Xaa Glu Phe Val Cys Trp Leu Leu Asp Thr Lys Xaa
20 25 30

<210> 14
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> D-Ser

<220>
<221> MISC_FEATURE

<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu spacer

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Xaa is gamma-Glu

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> C-terminal amidation

<400> 14

His Ser Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr Lys Xaa
20 25 30

<210> 15
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu spacer

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Xaa is AIB

<220>
<221> MOD_RES
<222> (27)..(27)
<223> Xaa is Methionine sulfoxide

<400> 15

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Xaa Asp Thr Lys Gln
20 25 30

<210> 16
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu spacer

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Xaa is AIB

<400> 16

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr Lys Gln
20 25 30

<210> 17
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu spacer

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Xaa is AIB

<220>
<221> MOD_RES
<222> (31)..(31)
<223> Xaa is gamma-Glu

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> C-terminal amidation

<400> 17

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Xaa
20 25 30

<210> 18
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu spacer

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> C-terminal amidation

<400> 18

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr
20 25

<210> 19
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> D-Ser

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu spacer

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> C-terminal amidation

<400> 19

His Ser Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr
20 25

<210> 20
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu spacer

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is AIB

<220>
<221> MOD_RES
<222> (31)..(31)
<223> D-Glu

<400> 20

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Lys Thr Lys Glu
20 25 30

<210> 21
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<223> Liraglutide

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Acylated with a C16 fatty acyl group via gamma-Glu spacer

<400> 21

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30

<210> 22
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Xaa is AIB

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu spacer

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Xaa is AIB

<220>
<221> MOD_RES
<222> (28)..(28)
<223> Xaa is Orn

<400> 22

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa
1 5 10 15

Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Xaa Asp Thr Lys Gln
20 25 30